LENEXA, Kan., January 11, 2022 / PRNewswire / – Synexis® LLC, a microbial reduction pioneer and sole developer of gaseous hydrogen peroxide and dry hydrogen peroxide (DHP ™) technology for occupied spaces, today announced positive new data from an analysis retrospective evaluating the use of DHP ™ technology in a clinical setting have been published in the current issue of the American Journal of Infection Control (AJIC). The retrospective analysis evaluated the effectiveness of DHP ™ technology, in addition to standard manual cleaning, in reducing nosocomial infections (HAIs) in the intensive care unit (ICU) of a pediatric oncology hospital. As an adjunct technology for environmental cleaning, DHP ™ has contributed to the reduction of HAIs in this clinical setting.

“Standard cleaning and disinfection protocols may not be sufficient for immunocompromised patients who are particularly susceptible to HAIs,” said Dr. Mario melgar, medical director for infections and control.

The study was conducted between January 2019 and november 2020 at the Pediatric ICU (USIP) of Unidad Nacional de Oncología Pediátrica (UNOP), the National Reference Center for Children with Cancer and a global partner of a leading pediatric cancer institution in the United States. UNOP is a 65-bed pediatric oncology hospital located in Guatemala City, Guatemala. Although they follow all CDC guidelines and protocols for the prevention of HAIs, DHP ™ technology has been added to the environmental standard cleaning and disinfection in the USIP to determine its effect on HAI levels. .

“This study demonstrates the value of DHP ™ technology. I am delighted to see the significant decrease in the incidence of C. diff in our PICU,” said Dr. Alicia chang, Department of Infectious Diseases. “We continue to follow the prevention and control strategies recommended by the CDC, and the addition of DHP ™ to our environmental cleaning process has helped to optimize our results. “

Between 2019 and 2020, adding DHP ™ to standard cleansing resulted in a 44.3% reduction in the incidence of HAIs (difference in incidence rate, IRD = -21.20, p = 0.0277) in PICU, including a 76.4% reduction in Clostridioides-associated gastroenteritis (IRD = -8.23, p = 0.0482), compared to the period preceding the installation of DHP ™. In addition, only one case of non-nosocomial respiratory infection associated with COVID-19 occurred in the PICU where DHP ™ was installed compared to a control area without DHP ™ which experienced an increase in infections. respiratory non-pneumonia acquired in hospital (IRD = 2.52; p = 0.028). This is consistent with recent studies indicating that DHP ™ inactivates SARS-CoV-2 both in air and on surfaces.2.3 Overall, exposure to DHP ™ resulted in a 61.4% reduction in the odds of contracting HAI during their stay (OR = 0.386; p = 0.029). The incidence of HAIs did not change significantly in another part of the hospital where DHP ™ was not installed.

“Nosocomial infections such as non-pneumonia respiratory infections associated with COVID-19 pose a serious threat that manual cleaning cannot completely eliminate,” said Eric Schlote, CEO of Synexis®. “We are delighted that DHP ™ technology continues to demonstrate its effectiveness in the clinical setting and may provide another layer of protection against HAIs and SARS-VOC-2. “

Study patients ranged from 1 month to 22 years old, with a mean age of 7.7 years. The majority (61%) were patients with leukemia, while the rest were diagnosed with other forms of cancer, including sarcoma, blastoma and lymphoma. These patients are at high risk for IAS due to their immunocompromised condition, exposure to invasive devices and procedures, and underlying medical conditions.4 DHP ™ technology reduced levels of SAIs without causing adverse events related to exposure to DHP ™.

Synexis® technology deploys DHP ™ to actively clean air and surfaces. DHP ™ molecules move around in an enclosed space to reduce viruses, bacteria, molds, odors and many insects. Generated from ambient humidity and oxygen naturally present in the environment, DHP ™ can be effectively delivered to occupied spaces at levels well below OSHA’s occupational aviation safety standards. that enables continued microbial reduction without disrupting normal operations and workflow.5 DHP ™ is capable of impacting contaminants in the air and on surfaces in hard to reach places.


Synexis develops cutting-edge bio-defense systems designed to transform the air in order to make the air and surfaces cleaner. Synexis BioDefense systems are regulated by the United States Environmental Protection Agency and state governments as antimicrobial devices. As a result, Synexis BioDefense systems are produced in an EPA registered facility and packaged and labeled in accordance with EPA regulations found in 40 CFR 152.500. The Synexis system is certified Underwriters Laboratories (UL2998) to not produce ozone and operates continuously without disruption to normal operations or work flow.6 Synexis currently holds 16 US patents, 17 of which are In addition, Synexis® DHP ™ technology is based on data from seven peer-reviewed studies.1,2,8,9,10,11,12

Founded in 2008, Synexis LLC is the leader in microbial reduction and the only developer of a patented technology that continuously creates and disperses DHP ™ (Dry Hydrogen Peroxide) to help reduce the presence of microbes in indoor spaces. 24 hours a day, without the need for occupants to vacate the space. Synexis has set the bar in the industry and continues to educate current and future customers on Indoor Environmental Quality (IQ).

For more information, visit

1 Mario melgar MARYLAND, Marylin Ramirez IA, Alicia chang MARYLAND, Federico Antillon MD, Impact of Dry Hydrogen Peroxide on Hospital-Acquired Infection at a Pediatric Oncology Hospital, AJIC: American Journal of Infection Control (2021), doi:
2 Huang, Y., Bilyeu, A., Hsu, W., Hettenbach, S., Willix, J., Stewart, S., Higgs, S., Vanlandingham, D., Treatment with dry hydrogen peroxide speeds up Decay of Severe Acute Coronavirus-2 Syndrome on Hard Non-Porous Surfaces, AJIC (2021)
3 Synexis. Efficacy of the Synexis sphere against SARS-CoV-2 Delta. 20 october 2021. Accessed december 2021.
4 Folgori L, Bernaschi P, Piga S, Carletti M, Cunha FP, Lara PH, de Castro Peixoto NC, Alves Guimarães BG, Sharland M, Araujo da Silva AR, Ciofi Degli Atti M. Infections associated with healthcare in pediatric intensive care and neonatal Units: Impact of underlying risk factors and antimicrobial resistance on 30-day lethality in Italy and Brazil. Infect Control Hosp Epidemiol. November 2016; 37 (11): 1302-1309. doi: 10.1017 / ice.2016.185. Published online August 11, 2016. PMID: 27511591
5 Occupational safety and health administration. Accessed August 14, 2020.
6 UL certification numbers: Blade UL E482400, Sentry UL E495096 and Sphere UL 2998.
seven Synexis Accessed November 30, 2021.
8 Sanguinet, J., Edmiston, C. Evaluation of dry hydrogen peroxide in reducing the microbial load in a healthcare setting. American Journal of Infection Control (AJIC) (2021).
9 Sanguinet, J., Lee, C. An efficient and automated approach to reduce the risk of infection of contaminated privacy curtains. AJIC (2021).
ten Herman, CK, Hess, J., Cerra, C. Dilute hydrogen peroxide technology for reduction of microbial colonization in hospital settings. AJIC (2015).
11 Melgar, M., et al. Effectiveness of dry hydrogen peroxide on reducing the risk of environmental microbial load in a pediatric oncology intensive care unit. AJIC (2020).
12 Melo, EF, McElreath, JS & Wilson, JL & Lara, Leonardo & Cox, NA & Jordan, Brian. (2020). Effects of a dry hydrogen peroxide disinfection system used in a cold room for eggs on hatchability and chick quality. Poultry science. Flight. 99, Nov 2020.


Comments are closed.